WBI-1001: A Non-steroidal and Non-immunosuppressive Anti-inflammatory Compound
WBI-1001 was discovered as a unique anti-inflammatory agent using the Company’s SYMBIOCHEM® drug discovery platform. The Company is focused on the development of WBI-1001 as a novel topical treatment for psoriasis and atopic dermatitis (a type of eczema) and a total 4 clinical studies for these two indications have been completed.
WBI-1001 has been shown to inhibit the expression of several pro-inflammatory cytokines directly associated with autoimmune and inflammatory diseases which have been targeted for many inflammatory diseases.
Clinical studies have demonstrated that 0.5 % and 1.0 % WBI-1001 creams are safe and well tolerated by patients with psoriasis or atopic dermatitis. In terms of efficacy, WBI-1001 has also shown very promising effectiveness against both psoriasis and atopic dermatitis.
Effective, safe and inexpensive topical treatment of psoriasis and eczema represent highly unmet medical needs. As a novel non-steroidal and non-immunosuppressive anti-inflammatory agent, WBI-1001 has an advantage over existing topical symptom-based therapies by targeting multiple aspects of the pathogenesis of the inflammatory diseases.